BACKGROUND: Inferences about long-term effects of therapies in multiple sclerosis (MS) have been based on surrogate markers studied in short-term trials. Preventing progressive disability is the key therapeutic goal but there remains no validated definition for its measurement in a trial context. Meanwhile, MS trials continue to shorten and to depend on unvalidated surrogates. Since there have been no treatment claims for improving unremitting disability, worsening of disability in the place...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Disability as an outcome in MS clinical trials.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record